J. Garst

发表

A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC).

H. Dressman, J. Nevins, A. Bild, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?

M. Socinski, R. Clough, M. Anscher, 2005, International journal of radiation oncology, biology, physics.

Cancer- and chemotherapy-induced anemia.

M. Millenson, R. Vij, C. Cleeland, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.

David H. Johnson, L. Schaaf, I. Dimery, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vaccine therapy in non—small-cell lung cancer

J. Garst, C. Albright, 2007, Current oncology reports.

Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.

R. Clough, M. Anscher, J. Herndon, 2003, International journal of radiation oncology, biology, physics.

Lung cancer in women

J. Garst, A. Coscio, 2006, Current oncology reports.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study

T. Lynch, A. Wozniak, Priya Kumar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I I S tudy o f I rinotecan P lus C isplatin i n P atients With A dvanced N on-Small-Cell L ung C ancer

L. Schaaf, I. Dimery, J. Garst, 1999 .

A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history

M. Berger, J. Rigas, F. Shepherd, 2007 .

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2

R. Govindan, J. Herndon, Mark R. Green, 2005, Cancer.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

M. Socinski, S. Zhou, M. Anscher, 2001, The oncologist.

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial

M. Stevenson, T. Stinchcombe, N. Ready, 2022, JTO clinical and research reports.

Vaccines for Lung Cancer

M. Morse, J. Garst, E. Toloza, 2004 .

Cancer- and treatment-related anemia: Clinical Practice Guidelines in Oncology

M. Millenson, G. Demetri, C. Cleeland, 2005 .

Cancer- and treatment-related anemia.

M. Millenson, G. Demetri, C. Cleeland, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS).

T. Lynch, A. Wozniak, S. Teng, 2010 .

Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS)

T. Lynch, Priya Kumar, S. Teng, 2008 .

A phase II multicycle trial of pegfilgrastim compared to Filgrastim after myelosuppressive chemotherapy

J. Crawford, J. Garst, C. Belani, 2000 .

Vinorelbine and Carboplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer

J. Crawford, M. O'Rourke, J. Garst, 2017 .

Growth inhibition of a human lung adenocarcinoma cell line by genetic complementation with chromosome 11.

G. Bepler, M. Campa, K. O'briant, 1997, Anticancer research.

Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.

R. Vollmer, D. Persons, J. Garst, 1998, American journal of clinical oncology.

Randomized, D ose-Escalation S tudy o f S D/01 C ompared With D aily F ilgrastim i n P atients R eceiving C hemotherapy

J. Crawford, J. Garst, L. Roskos, 2000 .

Diagnosis of posttransplant granulocytic sarcoma by fine‐needle aspiration cytology and flow cytometry

Katharine Liu, L. Dodd, J. Garst, 1999, Diagnostic cytopathology.

Genomic signatures in non-small-cell lung cancer: Targeting the targeted therapies

H. Dressman, A. Bild, A. Potti, 2006, Current oncology reports.

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

J. Rigas, F. Shepherd, M. Smylie, 2010, Clinical Cancer Research.

Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.

R. Clough, M. Anscher, J. Herndon, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

J. Le Pecq, H. Lyerly, M. Morse, 2005, Journal of Translational Medicine.

Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.

R. Figlin, J. Crawford, L. Harker, 1997, The New England journal of medicine.

How does the immune system attack cancer

O. Abdel-Wahab, D. Tyler, M. Kalady, 2004 .

Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial

P. Jänne, E. Vokes, Mark R. Green, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.

J. Crawford, J. Garst, J. Crawford, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perceptions of patients' self-efficacy for managing pain and lung cancer symptoms: correspondence between patients and family caregivers

C. McBride, F. Keefe, L. Fish, 2002, Pain.

Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium

M. Socinski, R. Clough, M. Anscher, 2004 .

PII: S0304-3959(02)00042-8

C. McBride, F. Keefe, L. Fish, 2002 .

A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-small Cell Lung Cancer

J. Herndon, J. Crawford, R. Riedel, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer.

R. Clough, L. Marks, J. Crawford, 2003, International journal of radiation oncology, biology, physics.

Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.

M. Dewhirst, R. Clough, M. Anscher, 2006, International journal of radiation oncology, biology, physics.

Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.

J. Crawford, R. Buller, J. Garst, 2005, Clinical lung cancer.

Caregiver-assisted coping skills training for lung cancer: results of a randomized clinical trial.

C. McBride, D. Baucom, F. Keefe, 2011, Journal of pain and symptom management.

Self-efficacy for managing pain, symptoms, and function in patients with lung cancer and their informal caregivers: Associations with symptoms and distress

C. McBride, D. Baucom, F. Keefe, 2008, PAIN®.

A pilot study investigating the utility of the cognitive-behavioral model of insomnia in early-stage lung cancer patients.

F. Keefe, J. Edinger, L. Porter, 2005, Journal of pain and symptom management.

Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients

W. Kraus, P. Douglas, D. Harpole, 2008, Cancer.

Attachment styles in patients with lung cancer and their spouses: associations with patient and spouse adjustment

F. Keefe, D. Davis, L. Porter, 2012, Supportive Care in Cancer.

Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer

J. Garst, B. J. Byrne, 2005, Current oncology reports.

Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.

R. Govindan, M. Kelley, R. Christenson, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Proactive recruitment of cancer patients' social networks into a smoking cessation trial.

G. Bepler, C. McBride, F. Keefe, 2011, Contemporary Clinical Trials.

Assessment of the Impact of Adjunctive Proactive Telephone Counseling to Promote Smoking Cessation among Lung Cancer Patients' Social Networks

G. Bepler, C. McBride, F. Keefe, 2013, American journal of health promotion : AJHP.

A phase I study of talotrexin (PT-523) in patients with relapsed or refractory non-small cell lung cancer (NSCLC).

G. Manikhas, A. Dowlati, J. Garst, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Dose-Dense Topotecan Given Upfront to Standard Therapy in Patients with Small Cell Lung Cancer

J. Herndon, J. Crawford, J. Garst, 2006, Clinical drug investigation.

Long-term complication risk after very high dose thoracic radiotherapy

R. Clough, M. Anscher, J. Herndon, 2002 .

Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

R. Govindan, E. Vokes, R. Kratzke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels.

G. Bepler, F. Keefe, B. Peterson, 2009, The journal of pain : official journal of the American Pain Society.

Distress and motivation for smoking cessation among lung cancer patients' relatives who smoke.

C. McBride, F. Keefe, L. Fish, 2003, Journal of cancer education : the official journal of the American Association for Cancer Education.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

M. Socinski, R. Clough, M. Anscher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.

J. Herndon, J. Crawford, M. Kelley, 2006, Lung cancer.

The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response.

L. Marks, D. Hollis, Sumin Zhou, 2007, International journal of radiation oncology, biology, physics.

Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS).

R. Robles, T. Lynch, D. Spigel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer

J. Garst, Jennifer Garst, 2007, Expert opinion on drug safety.

Journal of Translational Medicine BioMed Central

J. Le Pecq, H. Lyerly, J. Garst, 2007 .

Immunotherapy of surgical malignancies.

O. Abdel-Wahab, D. Tyler, M. Kalady, 2004, Current problems in surgery.

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

J. Rigas, F. Shepherd, M. Smylie, 2010, Clinical Cancer Research.